Arbutus Biopharma

700 Veterans Circle
United States

Tel: 267-469-0914


Show jobs for this employer

About Arbutus Biopharma

Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company’s current focus areas include Hepatitis B virus (HBV) and coronaviruses. In HBV, Arbutus is developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that they intend to combine to improve the outcomes of patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. Arbutus’ lead compound, AB-729 is the only RNAi therapeutic with evidence of immune re-awakening and is currently being evaluated in multiple phase 2 clinical trials. Arbutus has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including COVID-19). Arbutus is also exploring oncology applications for its internal PD-L1 portfolio.

Company Ownership: Public
Stock Symbol: ABUS
Stock Exchange: NASDAQ

415 articles with Arbutus Biopharma